GALWAY, Ireland, June 28,
2021
/PRNewswire-PRWeb/ -- Mirai Medical Ltd, a
manufacturer of a precision cancer therapy platform, announced the
first procedures at Rigshospitalet, University
of Copenhagen
, Denmark in a clinical trial to evaluate the
safety of Calcium electroporation treatment with EndoVE®, and
ePORE® a novel breakthrough technology that can treat
gastrointestinal cancers endoscopically.

The first procedure in the trial (EudraCT identification number:
2020-005787-58) was performed in a team led by Dr. Michael Achiam at the Department of surgery and
transplantation at Rigshospitalet. The trial aims to establish the
safety and feasibility of treating patients with advanced
oesophageal cancer in combination with local intratumoral injection
of a calcium based solution.

Pulsed electrical fields generated by the ePORE® and delivered
directly to the tumour by the EndoVE® endoscopic system results in
electroporation of the cells and allows for passive diffusion of a
locally injected calcium solution. Compared to healthy cells,
cancer cells are selectively less able to tolerate excessive
intracellular calcium and results in their death.

Developed exclusively at Mirai Medical, ePORE® therapy delivers
high frequency pulsed electrical fields to 'electroporate' the
tissue i.e. to make the cells porous, through the specifically
designed EndoVE® device which is applied directly to tumours in the
gastrointestinal tract. Unlike traditional methods used for tumour
destruction (radiotherapy used ionizing radiation; Radio frequency
uses heating, Cryoablation uses cooling), ePORE® therapy uses high
frequency pulsed electrical fields which are non-toxic and
preferentially target cancerous tissue leaving healthy tissues
intact.

"With this new treatment option we have an exciting possibility
to improve the treatment options for patients with upper
gastrointestinal cancer. There is a significant unmet clinical need
for these patients and we're excited about the potential to impact
positively on their quality of life," said Dr. Michael Achiam, study principal investigator and
upper GI surgeon at Rigshospitalet, University
of Copenhagen
, Denmark.

Oesophageal cancer is the 7th most common cause of cancer
morbidity and the 6th most common cause of cancer related death
worldwide. In western countries, incidence of adenocarcinoma (OAC),
a histological subtype of oesophageal cancer has increased by over
600% over the past 3 decades. With no specific symptoms of early
oesophageal cancers, most tumours are diagnosed at a late stage and
rapidly progress to an advanced stage when treatment options are
limited, and cure is not possible.

Dr. Declan Soden, PhD., CEO of
Mirai Medical added,
"We are delighted to see the first patient treated in the
Oesophageal Calcium EndoVE trial which is a very exciting
development and opens new possible treatment options for patients
with GI cancer. The idea of treating cancer by injecting it with
calcium and delivering a burst of electrical pulses is truly
pioneering and hopefully can lead to a new option being available
with less side effects for cancer patients."

About Mirai Medical
At Mirai Medical, we are passionate about developing technology
that greatly improves cancer outcomes and enhances patient
experiences. Following over 10 years of research and development,
Mirai Medical was formed from a team with over 30 combined years of
experience in the field of electroporation and pulsed electrical
fields for cancer, immunotherapy and medical device development to
address critical unmet challenges in global skin and
gastrointestinal cancer treatment. Our ePORE technology is a unique
precision therapy platform that targets tumour tissue whilst
preserving surrounding healthy tissue structure. Proven to be a
safe, simple and cost-effective technique, it greatly reduces side
effects and improves the experience of cancer patients. It is less
invasive and allows for faster treatment delivered as a day-case
procedure.

Media Contact

SEAN KINSELLA, Mirai Medical,
+353 873385064, [email protected]

Seán Kinsella, Mirai Medical, +353 91 442 498,
[email protected]

 

SOURCE Mirai Medical



Source link